CEO Deepa Prasad resigns effective March 29, 2022; Richard Nelson appointed Interim CEO

vTv Therapeutics Inc.

Prasad resigns as CEO/President/Board member, will serve as Strategic Advisor for 6 months.
Prasad receives $325,000 bonus, salary continuation for 15 months, retains 624,659 options.
Richard Nelson appointed Acting CEO until March 29 then Interim CEO; enters employment agreement.
Nelson to receive $200k base salary, 100% cash bonus for FY2022, options for 500,000 shares at $0.8060.
Board amended bylaws to allow appointment of Lead Independent Director.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Deepa Prasad

Chief Executive Officer

VTVT · vTv Therapeutics Inc.

Effective: 2022-03-29
Successor: Richard S. Nelson
Filed: March 3, 2022, 6:59 PM ET

On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of vTv Therapeutics Inc. (the “Company”) of her decision to resign from her positions as Chief Executive Officer, President and Board member, effective as of March 29, 2022

Appointed (interim)

Richard S. Nelson

Chief Executive Officer

VTVT · vTv Therapeutics Inc.

Effective: 2022-03-01
Filed: March 3, 2022, 6:59 PM ET

On March 1, 2022, the Board appointed Mr. Richard S. Nelson as Acting Chief Executive Officer until the Effective Date, at which time Mr. Nelson will become Interim Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Deepa Prasad resigned as Chief Executive Officer at vTv Therapeutics Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of vTv Therapeutics Inc. (the “Company”) of her decision to resign from her positions as Chief Executive Officer, President and Board member, effective as of March 29, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard S. Nelson was appointed as Chief Executive Officer at vTv Therapeutics Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On March 1, 2022, the Board appointed Mr. Richard S. Nelson as Acting Chief Executive Officer until the Effective Date, at which time Mr. Nelson will become Interim Chief Executive Officer

View on SEC.gov

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-000881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.